Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV vaccine - Institute of Human Virology/Profectus Biosciences

Drug Profile

HIV vaccine - Institute of Human Virology/Profectus Biosciences

Alternative Names: AIM Therapy - Profectus BioScience; anti-HIV antibodies - Profectus BioScience; FLSC vaccine; Full-length single chain vaccine; IHV 001; IHV 01

Latest Information Update: 28 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Profectus Biosciences
  • Developer Institute of Human Virology; Profectus Biosciences
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 28 Nov 2018 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (Parenteral)
  • 01 Jul 2018 Institute of Human Virology, in collaboration with Profectus Biosciences completes a phase I trial in HIV infections (In volunteers, Prevention) in USA (Parenteral) (NCT02756208)
  • 23 Apr 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV Infections (In volunteers) in USA , (NCT03505060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top